Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 11/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614720 | 0.86 | CHRNA7 (0.66) | NTMT1CHRNA7BCHEACHE | |
| SCHEMBL12614723 | 0.86 | CHRNA7 (0.66) | NTMT1CHRNA7BCHEACHE | |
| SCHEMBL29357375 | 0.86 | CHRNA7 (0.66) | NTMT1CHRNA7BCHEACHE | |
| SCHEMBL31522580 | 0.86 | NTMT1 (0.53) | NTMT1CHRNA7ALDH1A1BCHEACHE | |
| SCHEMBL19407264 | 0.86 | NTMT1 (0.62) | NTMT1CHRNA7BCHEACHE | |
| SCHEMBL12614806 | 0.86 | NTMT1 (0.57) | NTMT1CHRNA7ALDH1A1BCHEACHE | |
| SCHEMBL31522584 | 0.85 | CHRM3 (0.54) | NTMT1CHRNA7ALDH1A1BCHEACHE | |
| SCHEMBL12614523 | 0.84 | NTMT1 (0.52) | NTMT1CHRNA7ALDH1A1BCHEACHE | |
| SCHEMBL31591722 | 0.84 | ALDH1A1 (0.67) | NTMT1ALDH1A1 | |
| SCHEMBL16007003 | 0.84 | ALDH1A1 (0.67) | NTMT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3920912-B1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GENZYME CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3267983-B1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORP (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4100009-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | Genzyme Corporation (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | NTMT1 1645/4885CHRNA7 1975/4885ALDH1A1 1394/4885 |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GBA1, GBA2, CLN6 | NTMT1 1309/4885CHRNA7 813/4885ALDH1A1 3359/4885 |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, CMA1 | NTMT1 1379/4885CHRNA7 1796/4885ALDH1A1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.